Sarepta Therapeutics Could Be 22% Undervalued Following SRP 1003 Preclinical Data
Click to view quick news summary (Spoiler)
Sarepta Therapeutics released preclinical data for its SRP-1003 program, demonstrating significant knockdown of pathogenic DMPK RNA in myotonic dystrophy type 1 models.
Sarepta Therapeutics (SRPT) just put fresh preclinical data for its SRP-1003 program in front of specialists, showing up to roughly 80% knockdown of pathogenic DMPK RNA in myotonic dystrophy type 1 models.
That fresh Sarepta Therapeutics update landed against a tougher share price backdrop, with the stock at US$16.83 after a 30 day share price return that is down 19.6% and a year to date share price move that is down 21.0% as investors reassess both growth prospects and risk. Over a longer stretch, total shareholder return has fallen 24.2% over one year and 85.2% over three years, so any new clinical data like SRP-1003 tends to be viewed through a lens of rebuilding confidence rather than riding strong momentum.
Scan beyond Sarepta Therapeutics and consider other rare-disease and high-science opportunities using our hand picked 34 healthcare AI stocks, which could reward patience when sentiment turns back to clinical progress.
After that kind of drawdown, Sarepta Therapeutics at US$16.83 screens far below many fair value estimates. Is the market roughly right or is the gap to analyst targets too wide to ignore?
Most Popular Narrative: 22% Undervalued
On the most followed view, Sarepta Therapeutics screens well below an estimated fair value of $21.73, even after the recent drawdown to $16.83. That gap rests less on short term trading and more on how durable the Duchenne franchise and newer RNA programs prove to be.
Sarepta Therapeutics is using a cash flow positive Duchenne muscular dystrophy portfolio, with Q2 2026 product gross margins of 75% and non GAAP operating income of US$86 million, to self fund pipeline work and potentially support future earnings and cash generation without relying on new equity.
About DM1 and SRP-1003
Myotonic dystrophy type 1 (DM1) is the most common form of muscular dystrophy in adults and is caused by a repeat expansion in the DMPK gene. DM1 is a progressive, multisystem disorder that affects skeletal and smooth muscles, as well as the heart, respiratory system, eyes, and the endocrine, gastrointestinal, and central nervous systems. The condition is often characterized by muscle weakness, daytime sleepiness, respiratory difficulties, and cardiac conduction abnormalities. Currently, there is no cure for DM1, and no disease-modifying treatments exist.
SRP-1003 is an investigational siRNA-based therapy for DM1, designed to target and reduce—or "silence"—DMPK mRNA within target cells. SRP-1003 is currently being evaluated in a Phase 1/2, single-ascending-dose (SAD), randomized, placebo-controlled clinical trial (Study SRP-1003-101) involving individuals with DM1 aged 18 to 65.
About Sarepta Therapeutics
Sarepta is driven by an urgent mission: to develop precision genetic medicine for rare diseases that devastate lives and steal futures. We hold a leadership position in Duchenne muscular dystrophy and are building an extensive portfolio of programs targeting muscle, central nervous system, and cardiovascular diseases.
